In a phase I clinical trial, sixteen individuals with stage IIIB/IV NSCLC received intratumoral injections of the autologous dendritic cell-adenovirus CCL21 vaccine (NCT01574222), resulting in increased infiltration of CD8 + T cells and elevated expression of PD-L1 mRNA [53]. The gene discussed is CCL21; the disease is non-small cell lung carcinoma.